Please login to the form below

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the ... Exelixis’ drug could also be

Latest news

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
FDA’s year-end approvals take annual tally to 46

The closing few days of 2017 also saw line extension approvals for Exelixis and Novartis. ... therapy. Analysts at Leerink have suggested the new indication could catapult Exelixis’ cabozantinib franchise to $1bn in sales in 2025.
Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication. Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half
Pfizer's SMO inhibitor boosts survival in blood cancer trial

Other SMO inhibitors are also coming through development meanwhile, notably Exelixis/Bristol-Myers Squibb's BMS 833923 - in phase II testing for CML - and Ignyta/ Eli Lilly's taladegib which is

More from news
Approximately 4 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy. California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy. ... His familiarity with Exelixis and the biotech landscape should make for a seamless
Decibel Therapeutics expands leadership team

Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Frances Heller joins BMS senior management

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Digital Account Director: Salary TBC

Project Manager/ Account Manager: Salary TBC

Senior Medical Writer: Great salary and benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Marketing Agency: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....